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Introduction
B cell lymphoma 2 (Bcl-2) family members are critical regula-
tors of programmed cell death (van Delft and Huang, 2006). 
Proteins of this family share homology in four conserved re-
gions termed Bcl-2 homology (BH) domains and can be divided 
into anti- and proapoptotic proteins. The antiapoptotic proteins 
Bcl-2, Bcl-xL, Bcl-w, myeloid cell leukemia (Mcl) 1, and Bfl  -1/A1 
are characterized by all four BH domains. Proapoptotic ho-
mologues can be further subdivided into two subfamilies. 
The multi–BH domain Bax homologues, including Bax, Bak, 
and Bok/Mtd, contain BH1–3, whereas the proteins of the BH3-
only subfamily, which comprise Bad, Bid, Bim, Bmf, Puma, Noxa, 
Nbk/Bik, and Hrk, only share the BH3 domain. BH3-only pro-
teins are essential initiators of apoptosis, and once activated, 
they regulate the ability of the multi–BH domain members Bax 
and Bak to undergo a conformational switch and to oligomerize 
in the outer mitochondrial membrane (Desagher et al., 1999; 
Wei et al., 2000). Activated Bax and Bak then induce mito-
chondrial membrane permeabilization and subsequent release of 
proapoptotic factors, e.g., cytochrome c, from the intermembrane 
space into the cytosol. Cytosolic cytochrome c induces forma-
tion of the apoptosome and ultimately triggers execution of the 
intrinsic apoptosis signaling cascade.
Deregulation of Bcl-2 family proteins has been implicated 
in the development of many malignancies (Cory et al., 2003). 
In addition to deregulated expression of antiapoptotic Bcl-2 
(Strasser et al., 1990), disruption of multidomain proapoptotic 
Bcl-2 homologues is also critically involved in tumorigenesis. 
Loss of Bax is a frequent event in human cancer and is related 
to tumor progression, poor prognosis, and clinical resistance 
to anticancer therapy (Bargou et al., 1995; Sturm et al., 2001). 
Furthermore, loss of the bax gene contributes to oncogenic trans-
formation and tumor development in mice (Yin et al., 1997). 
Recently, it has been shown that inactivation of BH3-only pro-
teins is implicated in human cancer (Tagawa et al., 2005). In line 
with a tissue-specifi  c expression of the BH3-only protein Nbk/Bik 
(Boyd et al., 1995; Han et al., 1996) with strong expression 
in the kidney (Daniel et al., 1999), loss of Nbk and the more 
broadly expressed Bim is a common feature of clear cell renal 
cell carcinoma (Sturm et al., 2006; Zantl et al., 2007).
Bcl-2 family members can form homo- and heterodimers 
with other members of the protein family. It is considered that 
the BH3 domain constitutes an amphipathic α helix, which 
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  B 
cell lymphoma 2 (Bcl-2) homology domain 3 (BH3)–
only proteins of the Bcl-2 family are important func-
tional adaptors that link cell death signals to the 
activation of Bax and/or Bak. The BH3-only protein Nbk/
Bik induces cell death via an entirely Bax-dependent/Bak-
independent mechanism. In contrast, cell death induced 
by the short splice variant of Bcl-x depends on Bak but not 
Bax. This indicates that Bak is functional but fails to be-
come activated by Nbk. Here, we show that binding of 
myeloid cell leukemia 1 (Mcl-1) to Bak persists after Nbk 
expression and inhibits Nbk-induced apoptosis in Bax-
deﬁ  cient cells. In contrast, the BH3-only protein Puma dis-
rupts Mcl-1–Bak interaction and triggers cell death via 
both Bax and Bak. Targeted knockdown of Mcl-1 over-
comes inhibition of Bak and allows for Bak activation by 
Nbk. Thus, Nbk is held in check by Mcl-1 that interferes 
with activation of Bak. The ﬁ  nding that different BH3-only 
proteins rely speciﬁ  cally on Bax, Bak, or both has impor-
tant implications for the design of anticancer drugs target-
ing Bcl-2.
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binds to a hydrophobic groove formed by the BH1, BH2, and 
BH3 domain of antiapoptotic Bcl-2 family members. Binding 
to and inactivation of antiapoptotic Bcl-2 family members is 
crucial for BH3-only proteins to initiate apoptosis (Willis et al., 
2005). The ability of proapoptotic Bcl-2 family proteins to 
  interact with their antiapoptotic siblings led to the so-called 
rheostat model: the ratio of pro- to antiapoptotic Bcl-2 members 
determines the apoptotic fate of the cell (Korsmeyer et al., 1993). 
A recent study revealed, however, that BH3-only proteins selec-
tively bind to specifi  c sets of prosurvival proteins and that only 
certain pairs associate with each other under physiological condi-
tions (Chen et al., 2005). These complementary binding profi  les 
implicate two classes of antiapoptotic Bcl-2 proteins, one com-
prising Mcl-1 and Bfl  -1/A1, the other Bcl-2, Bcl-xL, and Bcl-w. 
It has been suggested that effi  cient induction of apoptosis de-
pends on neutralization of both classes of prosurvival proteins.
Moreover, numerous studies show a central role of Bax 
rather than Bak in Bcl-2–regulated cell death. This is espe-
cially true for Puma and Nbk, which both have been shown to 
act via a Bax-dependent/Bak-independent pathway (Theodorakis 
et al., 2002; Gillissen et al., 2003; Yu et al., 2003). There is 
also accumulating evidence that distinct BH3-only proteins act 
specifi  cally through the activation of Bak (Cartron et al., 2003; 
Lindenboim et al., 2005). We have shown that disruption of 
Bax is suffi  cient to confer resistance to Nbk under conditions 
of abiding Bak expression. This indicates that induction of cell 
death by Nbk is mediated specifi  cally via a Bax-dependent and 
apparently Bak-independent pathway (Gillissen et al., 2003). 
In this light, the role of Bak and putative Bak inhibitors in 
Nbk-induced apoptosis remains enigmatic. Thus, we cannot 
rule out the possibility that loss of Bax protects cells just 
by decreasing the amount of Bax/Bak-like molecules under 
a critical threshold, which would be necessary for Nbk to in-
duce apoptosis.
Here, we show that Bak is fully functional and suffi  cient to 
mediate apoptosis by specifi  c activators, e.g., Bcl-xS. Moreover, 
evidence is provided for the mechanism underlying Nbk resis-
tance in Bax-defi  cient cells. Although Nbk triggers Bax activa-
tion, it nevertheless fails to relieve Mcl-1–mediated inhibition of 
Bak. Moreover, Mcl-1 protein levels are increased upon Nbk 
expression. By this mechanism, Nbk enforces inhibition of Bak 
by Mcl-1. Collectively, these results provide a molecular ratio-
nale for the Bax dependency of the BH3-only protein Nbk.
Results
We have shown previously that loss of Bax protects cancer cells 
from apoptosis induced by the BH3-only protein Nbk (Gillissen 
et al., 2003). To further investigate the mechanism of Nbk-
induced cell death and to study the regulation of the Bax 
homologous protein Bak in detail, we induced expression of a 
myc-tagged Nbk protein in the parental wild-type (wt) HCT116 
cell line and in isogeneic cell lines devoid of Bax (Bax
−) or Bak 
(Bak
−) expression alone or of both (Bax
−/Bak
−; Fig. 1 A). Loss 
of protein expression was achieved by knockout of the Bax gene 
(Zhang et al., 2000) and Bak knockdown by short hairpin RNA 
(Theodorakis et al., 2002), respectively.
Transduction of these cell lines with an adenoviral vector, 
Ad-mycNbk-tTA, for the regulated expression of Nbk leads to 
high levels of Nbk protein in the absence of doxycycline, i.e., 
under on conditions, whereas expression of the transgene was 
almost completely repressed by the addition of doxycycline to 
the culture medium, i.e., under off conditions (Fig. 1 B). Western 
blot analyses showed that forced expression of Nbk is accom-
panied by cleavage of the initiator caspase-9 and the effector 
  caspase-3 in HCT116 wt and in HCT116 Bak
− (knockdown) 
cells. In contrast, neither caspase-9 nor caspase-3 cleavage 
could be detected in HCT116 cells devoid of Bax expression, 
regardless of whether or not they expressed Bak. This is not 
caused by lower Nbk expression because Western blot analyses 
affi  rmed equal expression levels of Nbk under on conditions in 
all four cell lines.
To confi  rm that loss of Bak does not affect regulation of 
apoptosis upon Nbk expression, we performed fl  ow cytometric 
analyses to quantify fragmentation of genomic DNA. Apoptotic 
cells were identifi  ed as cells with hypodiploid, i.e., sub-G1, 
DNA content. After 24 h of transduction with Ad-mycNbk-tTA, 
a mean of  40% of the HCT116 wt and 45% of the HCT116 
knockdown cells became apoptotic under on conditions (Fig. 1 C). 
In sharp contrast, identical transduction with Ad-mycNbk-tTA 
failed to signifi  cantly induce apoptosis in Bax knockout and 
Bax/Bak double defi  cient HCT116 cells. These results establish 
that, at least in Nbk-induced apoptosis, Bax and Bak do not 
  exert redundant functions. Whereas Bak knockdown does not 
affect Nbk-induced apoptosis, loss of Bax effi  ciently protects 
HCT116 cells from Nbk-induced apoptosis. Furthermore, the 
presence of Bak does not infl  uence the proportion of cells under-
going Nbk-induced apoptosis, regardless of whether or not they 
express Bax.
To corroborate that all death occurs by apoptosis and to 
control viability, we analyzed cells induced to express Nbk by 
propidium iodide (PI)/Annexin V–FITC staining. As in the case 
of the DNA fragmentation analysis, Nbk induced apoptosis in 
the HCT116 wt cells and in Bak-defi  cient HCT116 cells, as 
analyzed by detection of phosphatidylserine exposure and PI 
negativity (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200703040/DC1). Under on conditions, 41% of wt cells 
were detected as Annexin V positive/PI negative (early apop-
totic) and an additional 13% showed Annexin V/PI positivity 
(late apoptotic) at 24 h after transduction with Ad-mycNbk-tTA. 
In contrast to Bak knockdown cells, Bax-defi  cient cell lines dis-
played <6% of Annexin V–positive/PI-negative cells and only 
6% of double positive cells.
To further address the role of Bax and Bak and of mito-
chondria in Nbk-induced apoptosis, we determined the release 
of cytochrome c and dissipation of the mitochondrial membrane 
potential upon exposure to Ad-mycNbk-tTA. Western blot anal-
ysis of cytosolic extracts obtained at 24 h after infection with 
Ad-mycNbk-tTA showed that Nbk expression induces the re-
lease of cytochrome c in both HCT116 wt and HCT116 Bak
− 
cells but not in Bax-defi  cient cell lines (Fig. 2 A).
Using the potential-sensitive dye JC-1, we used fl  ow cytom-
etry to analyze whether release of cytochrome c is accompanied by 
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membrane potential (∆Ψm). This revealed loss of ∆Ψm in Bax-
profi  cient cells upon mycNbk expression, regardless of the presence 
or absence of cellular Bak. This loss of ∆Ψm occurred in a mean 
of 42 and 62% of the HCT116 wt and HCT116 Bak
− cells, respec-
tively. Conversely, only 16% of the Bax knockout and 10% of 
Bak/Bax double defi  cient cells exhibited decreased mitochondrial 
membrane potential upon Ad-mycNbk-tTA trans  duction under 
on conditions (Fig. 2, B and C). Compared with HCT116 wt 
cells, induction of cell death by Nbk is slightly increased in Bax
+ 
cells (Figs. 1, S1, and S2, available at http://www.jcb.org/cgi/
content/full/jcb.200703040/DC1). This is not caused by a decrease 
in the level of antiapoptotic proteins such as Bcl-2 or Bcl-xL (not 
depicted), but it seems to refl  ect the increased Bax expression 
level in these cells (Fig. 1 A).
These data demonstrate that loss of Bax, but not of Bak, 
expression protects HCT116 cells from Nbk-induced apoptosis. 
Nevertheless, regarding the simple rheostat model of a balance 
between pro- and antiapoptotic proteins, we could not rule out 
that loss of Bax protects cells just by decreasing the amount of 
proapoptotic multi–BH domain proteins under a critical thresh-
old necessary for Nbk to induce apoptosis. Thus it might be 
that, in Bax-defi  cient cells, the amount of Bak protein is not 
suffi  cient to mediate apoptotic signals by Nbk. To test if in-
creased expression levels of proapoptotic multi–BH domain 
proteins can sensitize cells for Nbk-induced apoptosis, we es-
tablished cell lines in which Bax or Bak is constitutively over-
expressed. The parental cell line DU145 does not express Bax 
because of a frameshift mutation in the bax gene, whereas bak 
is not mutated and endogenous Bak is expressed to a moderate 
extent. By use of a retroviral vector, HyTK-Bax, we established 
DU145 cells stably reexpressing the Bax-α cDNA under the 
control of a cytomegalovirus (CMV) promoter (von Haefen 
et al., 2002) and a Bax-negative vector control cell line (Fig. 3 A). 
Infection of these cell lines with Ad-mycNbk-tTA resulted in 
comparable levels of Nbk expression in both cell lines under on 
conditions (Fig. 3 A).
Flow cytometric analysis of DNA fragmentation revealed 
that Nbk expression failed to induce apoptosis in the Bax-negative 
Figure 1.  Nbk expression induces caspase processing and 
apoptotic DNA fragmentation in HCT116 wt and HT116 Bak-
deﬁ  cient cells but not in Bax knockout cells. (A) Bax and Bak 
expression levels in different HCT116 cell lines. (B) Western 
blot analysis for Nbk expression and caspase 9 and 3 cleav-
age. HCT116 cells were infected with the recombinant adeno-
virus Ad-mycNbk-tTA and cultured for 24 h in the presence 
(off) or absence (on) of doxycycline (Dox). Control cells were 
mock treated and grown in the absence of doxycycline. *, un-
speciﬁ  c band. (C) Flow cytometric measurement of DNA con-
tent. Cells were treated as described in B. Cells displaying a 
sub-G1 hypodiploid DNA content are considered apoptotic. 
Data are means ± SD from three independent experiments.JCB • VOLUME 179 • NUMBER 4 • 2007  704
control cells. Despite strong Nbk expression, only 7% of the 
cells showed hypodiploid DNA content, compared with 5 and 
6% under control and off conditions, respectively. In con-
trast, Bax-expressing DU145 cells readily underwent apoptotic 
DNA fragmentation with 39% of Bax-reexpressing DU145 cells 
showing sub-G1 DNA content (Fig. 3 B). This confi  rms the 
Bax dependency of Nbk-induced cell death observed in the 
HCT116 system.
In parallel, we generated DU145 cells stably overexpress-
ing Bak by the use of a CMV promoter–driven pcDNA3-Bak 
vector as previously described (Hemmati et al., 2006). DU145 
control cells, transfected with an empty vector, show moderate 
Bak expression, whereas transfection of DU145 cells with 
pcDNA3-Bak resulted in high Bak protein expression (Fig. 3 A). 
Transduction with Ad-mycNbk-tTA resulted in high and com-
parable expression of Nbk under on conditions. However, in 
sharp contrast to Bax, Bak failed to sensitize the DU145 cells 
for apoptosis induction in response to Nbk expression (Fig. 3 B). 
We have shown previously that Bak overexpression in Bax- negative 
DU145 cells sensitizes for DNA damage–induced apoptosis by 
the topoisomerase II poison epirubicin (von Haefen et al., 2004). 
Thus, the resistance of Bax-defi  cient DU145 cells to Nbk-
induced apoptosis is not caused by an insuffi  cient function 
of the Bak protein. This underlines the idea that, in contrast to 
Bax, functional Bak is not suffi  cient to transduce the cell death 
signal triggered by Nbk. This is in contrast to other BH3-only 
proteins, which trigger apoptosis via Bak- or Bax/Bak-dependent 
pathways. Notably, Bcl-xS–induced apoptosis is entirely depen-
dent on Bak, but not on Bax, in mouse embryonic fi  broblasts 
(Lindenboim et al., 2005). This is in line with our results ob-
tained in the DU145 system. Bax-overexpressing DU145 cells 
were resistant to Bcl-xS, whereas Bak-overexpressing DU145 
cells were highly sensitized for induction of apoptosis by Bcl-xS 
(Fig. 3 C). These results confi  rm that Bak is functional. Thus, 
the failure of Bak to become activated by Nbk is not caused by 
an impaired Bak protein.
To further investigate the specifi  c role of Bax and Bak 
in Nbk-induced apoptosis, we generated DU145 cells stably 
Figure 2.  Nbk-induced cytochrome c release and mitochondrial 
transmembrane permeability transition are impaired in Bax- but not 
in Bak-deﬁ  cient cells. HCT116 wt, Bax
−, Bak
−, and Bax
−/Bak
− cells 
were transduced with Ad-mycNbk-tTA and cultured for 24 h under off 
or on conditions. Control cells were mock treated and grown in the 
absence of doxycycline. (A) Cytosolic extracts were prepared from 
HCT116 cell lines and subjected to Western blot analysis for cyto-
chrome c. (B) HCT116 cells were labeled with JC-1. Decreased red 
ﬂ  uorescence intensity was measured by ﬂ  ow cytometry (representa-
tive experiment). The percentage of cells with ∆ψm loss is indicated 
between markers. (C) Data are means ± SD from three independent 
experiments of cells with ∆ψm loss.CONTROL OF BAK BY MCL-1 IN NBK RESISTANCE • GILLISSEN ET AL. 705
  expressing EGFP fusion proteins of Bax or Bak. To this end, 
the cDNA for Bax or Bak was inserted into the pEGFP-C1 vec-
tor, and resulting plasmids were transfected into DU145 cells. 
In agreement with an expected cytosolic localization of Bax, 
EGFP-Bax showed a homogenous, mostly cytoplasmic staining 
pattern (Fig. 4 A), with some Bax being localized constitutively 
at the mitochondria (Fig. 4 B). EGFP-Bak showed a different 
  reticular localization, which corresponds to constitutive associa-
tion of Bak with, e.g., mitochondrial membranes and the ER 
(Fig. 4 A; and see Fig. 8 C). Nbk expression induced a strong 
clustering of EGFP-Bax after 24 h, which indicates quantitative 
redistribution of Bax from the cytosol to the mitochondria and 
oligomerization of activated Bax. In contrast to EGFP-Bax, and 
despite the fact that translocation is not necessary in the case of 
Bak, negligible redistribution of EGFP-Bak was detected under 
on conditions (Fig. 4 A). This effect was far less than the effect 
observed for EGFP-Bax. Exposure to the anticancer drug 5-FU 
or Bcl-xS did, however, trigger massive clustering of Bak (von 
Haefen et al., 2004; unpublished data). Upon Nbk expression, 
EGFP-Bax coalesces into clusters that remain closely associated 
with mitochondria (Fig. 4 B). There, Bax localizes to mito-
chondrial tips and constriction sites, associates with Drp1 and 
Figure 3.  Inverse role of Bax and Bak in apoptosis induced by Nbk or Bcl-xS. DU145 wt cells and DU145 Bax- or Bak-overexpressing cell lines were trans-
duced with Ad-mycNbk-tTA and cultured under off or on conditions. Control cells were mock treated and grown in the absence of doxycycline. (A) Western 
blot analyses of Bax and Bak expression levels in different DU145 cell lines (top blots) and of induced Nbk expression (bottom blots). (B) Flow cytometric 
measurement of hypodiploid DNA after Nbk expression. The percentage of apoptotic cells was measured 24 h after adenoviral transduction. (C) Flow cyto-
metric measurement of hypodiploid DNA after Bcl-xS expression. Cell lines were transduced with Ad-mycBcl-xS und cultured as described in Materials and 
methods. The percentage of apoptotic cells was measured 24 h after adenoviral tranduction. Data are means ± SD from three independent experiments.JCB • VOLUME 179 • NUMBER 4 • 2007  706
Mfn2, and participates in apoptotic fragmentation of mitochondria 
(Nechushtan et al., 2001; Karbowski et al., 2002). Eventually, 
EGFP-Bax is located in small punctate structures. During this 
process, mitochondria cluster around the nucleus and cells under-
going apoptosis shrink and show rounded shape (Fig. S2).
These data establish that Nbk is unable to induce apopto-
sis via a Bak-dependent pathway. We therefore aimed to test 
whether this is caused by the presence of an endogenous Bak 
inhibitor. Because of its constitutive membrane association, 
Bak is kept tightly in check by its binding to inhibitory proteins, 
such as VDAC2, and prosurvival members of the Bcl-2 family. 
As activation of Bak is reported to be specifi  cally inhibited by 
two prosurvival members of the Bcl-2 family, Bcl-xL and Mcl-1 
(Willis et al., 2005), we investigated interaction of Nbk with 
these proteins by coimmunoprecipitation studies. To this end, 
we used Bax-profi  cient DU145 cells expressing myc-tagged Nbk. 
MycNbk was precipitated and the resulting samples were exam-
ined for the presence of Mcl-1 and Bcl-xL by Western blot analysis. 
Mcl-1 could not be detected in anti-Nbk immunopreci  pitates 
(Fig. 5 A, left, on), indicating that Nbk does not interact with 
Mcl-1. However, the opposite was true for Bcl-xL, which was 
readily detected in Nbk immunoprecipitates, thereby confi  rming 
that Nbk specifi  cally binds to Bcl-xL. Additionally, as neither 
Bax nor Bak interact with Nbk, Nbk appears to act as a de-
repressor, which inhibits Bcl-xL function, rather than a direct 
activator of proapoptotic Bax-like molecules.
Figure 4.  Nbk expression induces oligomerization and clustering of EGFP-Bax but not -Bak. (A) DU145 cells stably expressing EGFP-Bax or -Bak were 
transduced with Ad-mycNbk-tTA and cultured under off or on conditions. 24 h after infection of the cells, images were acquired by the use of a ﬂ  uorescent 
microscope. Bar, 50 μm. (B) Subcellular localization pattern of EGFP-Bax. Mitochondria of DU145 EGFP-Bax cells were stained red by the use of an anti-
body against the Tom 20 protein and counterstained for DNA with DAPI. Bax shows a diffuse pattern of localization in nonapoptotic cells, concordant with 
its preferentially cytoplasmic localization (top). After Nbk expression Bax coalesces into large clusters adjacent to mitochondria (bottom). Bar, 25 μm.CONTROL OF BAK BY MCL-1 IN NBK RESISTANCE • GILLISSEN ET AL. 707
On the basis of a recent publication by Chen et al. (2005), 
which demonstrated high affi  nity of the Puma BH3 peptide to 
all antiapoptotic Bcl-2 proteins, we expressed Puma in DU145 
Bax cells as a control. Both Mcl-1 and Bcl-xL were detected in 
anti-Puma immunoprecipitates (Fig. 5 A, right, on). This indi-
cates that, in contrast to Nbk, Puma targets both antiapoptotic 
proteins, Bcl-xL and Mcl-1, in vivo. In line with the assumption 
that Puma, like Nbk, functions as a derepressor, we did not ob-
serve previously reported interactions of Bax with a Puma BH3 
domain in a cell-free system (Kuwana et al., 2005) or of Bax 
with Puma in vivo (Cartron et al., 2004). Neither did we observe 
an interaction of Puma with Bak. A reciprocal immunoprecip-
itation was also performed to confi  rm the aforementioned data. 
This time, Mcl-1 was precipitated from DU145 Bax cells over-
expressing Nbk or Puma. In accordance with the immuno-
precipitations described in Fig. 5 A, Nbk was not detectable in 
anti–Mcl-1 immunoprecipitates (Fig. 5 B, left, on), whereas Puma 
was readily detected in Mcl-1 immunoprecipitates (Fig. 5 B, 
right, on). These data demonstrate that different BH3-only pro-
teins target different antiapoptotic Bcl-2 family members in a 
cellular context. This is well supported by Biacore data showing 
specifi  c interactions of BH3 domain peptides with antiapoptotic 
Bcl-2 family proteins (Chen et al., 2005).
We next asked if Nbk or Puma might differentially disrupt 
the Mcl-1–Bak interaction. Under off conditions, Bak can be 
  detected in anti–Mcl-1 immunoprecipitates (Fig. 5 B). Despite 
high levels of Nbk expression under on condition, this Mcl-1–
Bak interaction is not disturbed by Nbk (Fig. 5 B, left). In con-
trast to Nbk, Puma binds to Mcl-1 and displaces Bak, as Bak is 
no longer detectable in anti–Mcl-1 immunoprecipitates after 
Puma expression (Fig. 5 B, right). Mcl-1 interacts with Bak (but 
not with Bax), as Bak (but not Bax) was detectable in anti–Mcl-1 
immunoprecipitates (Fig. 5 B). This was observed under condi-
tions that promote association of prosurvival proteins with Bax, 
i.e., the use of nonionic detergent Triton X-100. In contrast, 
no such fi  ndings have been reported for Bak, and Bak has also 
been shown to associate with Mcl-1 in the presence of CHAPS. 
Collectively, these interaction studies indicate that Nbk, in con-
trast to Puma, is insuffi  cient to displace Bak from Mcl-1, as Nbk 
specifi  cally interacts with Bcl-xL but not with Mcl-1.
Interestingly, we found that Mcl-1 expression is increased 
in cells expressing Nbk. Inhibition of Bak by Mcl-1 might be 
enforced by this stabilization of Mcl-1. In this regard, a recent 
study showed that the BH3-only protein Puma also stabilizes 
Mcl-1 levels (Mei et al., 2005). To investigate Mcl-1 stabiliza-
tion, we blocked proteasomal degradation of Mcl-1 by the use 
of the ubiquitin proteasome inhibitor MG132 or induced ex-
pression of Puma and compared Mcl-1 levels to those upon Nbk 
expression in DU145 cells. Western blot analysis revealed that 
inhibition of the proteasome by MG132 and expression of Puma 
lead to increased levels of Mcl-1, and expression of Nbk gave 
comparable results (Fig. 6). However, in contrast to Puma, which 
may stabilize Mcl-1 through direct interactions (Mei et al., 2005), 
Nbk does not bind to Mcl-1. Thus, other and/or indirect mecha-
nisms must be involved in the up-regulation of Mcl-1 in re-
sponse to Nbk expression. As shown by coimmunoprecipitation 
Figure 5.  Coimmunoprecipitation analyses of Bcl-2 family 
member interaction. (A) In contrast to Puma, which targets 
Mcl-1 and Bcl-xL, Nbk does not bind to Mcl-1. DU145 Bax cells 
were transduced with Ad-mycNbk-tTA or Ad-mycPuma-tTA and 
cultured under off or on conditions for 24 h. Lysates of cells sol-
ubilized in Triton X-100 buffer were immunoprecipitated with 
anti-Nbk (left) or anti-Puma (right) antibody. Immune complexes 
were resolved by SDS-PAGE, and proteins were detected by 
immunoblotting as indicated by arrows. (B) Mcl-1–Bak inter-
action persists despite Nbk expression, whereas Puma ex-
pression disrupts the Mcl-1–Bak complex. Cell lysates were 
prepared as described in A and immunoprecipitated with 
anti–Mcl-1 antibody. S, supernatant; P, immunoprecipitate.JCB • VOLUME 179 • NUMBER 4 • 2007  708
experiments, Puma binds to Bcl-xL, and additional overexpression 
of Nbk strongly reduces this interaction (Fig. S3, available at 
http://www.jcb.org/cgi/content/full/jcb.200703040/DC1). It might 
be that Puma is displaced from Bcl-xL after Nbk expression and 
then is available to bind and stabilize Mcl-1. However, expression 
levels of Puma are moderate in DU145 cells, and expression of 
Nbk leads to Mcl-1 stabilization, even after down-regulation of 
Puma by siRNA (Fig. 6). Thus, stabilization of Mcl-1 by Nbk 
is independent of Puma. Furthermore, stabilization of Mcl-1 by 
Nbk or Puma is specifi  c, as expression levels of Bcl-xL and Bcl-2 
(which is barely detectable in DU145) do not change after Nbk 
or Puma expression (Fig. 6).
To functionally address the contribution of Mcl-1 in Bak reg-
ulation during Nbk-induced cell death, we down-regulated Mcl-1 
by RNA interference in Bax-defi  cient and Bax-reexpressing 
DU145 cells (Fig. 7 A). Mcl-1 expression was specifi  cally 
decreased in both cell lines by Mcl-1 siRNA but not by control 
siRNA. As expected, Bax-defi  cient DU145 cells were resistant 
to Nbk-induced apoptosis, and reconstitution of Bax sensitized 
these cells for Nbk-induced apoptosis. Lipofection of Mcl-1 
siRNA sensitized both Bax-defi  cient and -profi  cient DU145 
cells for Nbk-induced apoptosis, whereas an irrelevant control 
siRNA had no effect (Fig. 7 B). Consistent with these data, 
Nbk-triggered release of cytochrome c is increased after down-
regulation of Mcl-1. DU145 cells treated with control siRNA 
did not show cytochrome c release, whereas Mcl-1 siRNA causes 
release of cytochrome c after Nbk expression in these Bax-defi  cient 
cells (Fig. 7 C). In Bax-profi  cient DU145 cells, cytochrome c 
release was increased by Mcl-1 siRNA but not by control siRNA. 
Measurement of phosphatidylserine exposure and PI uptake con-
fi  rmed the increased numbers of apoptotic cells upon Mcl-1 down-
regulation. Although Bax-defi  cient DU145 cells were resistant 
to Nbk-induced phosphatidylserine exposure, reconstitution of 
Bax sensitized these cells for Nbk-induced apoptosis. Further-
more, down-regulation of Mcl-1 sensitized both cell lines for 
Nbk-induced phosphatidylserine exposure. About 26% of DU145 
mock cells were detected as Annexin V positive (13.5% late 
apoptotic [PI positive] and 12.5% early apoptotic [PI negative]). 
Overall, 40% of Bax-reexpressing DU145 cells were stained 
with Annexin V–FITC (16.5% late and 24% early apoptotic; 
Fig. S4, available at http://www.jcb.org/cgi/content/full/jcb
.200703040/DC1). Thus, knockdown of Mcl-1 renders Bax-
defi  cient/Bak-expressing DU145 cells susceptible to Nbk-induced 
cytochrome c release and apoptosis.
During apoptosis, Bak undergoes a conformational change 
leading to the exposure of an N-terminal epitope. To study if 
Nbk-induced apoptosis results in Bak activation after siRNA re-
pression of Mcl-1 in Bax-defi  cient DU145 cells, we performed 
immunofl  uorescent stainings with a conformation-specifi  c anti-
body directed against the Bak N terminus. siRNA-mediated 
down-regulation of Mcl-1 enabled Nbk to induce Bak activation 
in DU145 cells, whereas an irrelevant control siRNA had no 
effect (Fig. 8 A). In agreement with the conformational change 
of Bak, Nbk expression induced a strong clustering of EGFP-
Bak after Mcl-1 knockdown (Fig. 8 B). In contrast, cells treated 
with control siRNA showed no EGFP-Bak clustering after in-
duction of Nbk expression.
In Bax-defi  cient DU145 cells treated with Mcl-1 siRNA, 
EGFP-Bak, unlike EGFP-Bax, constitutively colocalized with 
mitochondria in healthy cells and was not detected in the cytosol 
(Fig. 8 C, left). Upon activation of Bak by induced expression 
of Nbk, EGFP-Bak, like EGFP-Bax, localized to mitochondrial 
tips and coalesced into large clusters that remained associated 
with mitochondria (Fig. 8 C, right). Eventually the phenotype 
is comparable to EGFP-Bax, with small punctate EGFP-Bak 
structures, clustering of mitochondria, and a round-up apoptotic 
shape off the cells (Fig. S5, available at http://www.jcb.org/cgi/
content/full/jcb.200703040/DC1).
According to a recent paper, Bak is not only sequestered 
by Mcl-1 but also by Bcl-xL (Willis et al., 2005). To study if 
Nbk can inactivate Bcl-xL to release and activate Bak, we per-
formed coimmunoprecipitation experiments using a Bcl-xL–
specifi  c antibody (Fig. 8 D). Both Bax and Bak can be detected 
in anti–Bcl-xL immunoprecipitates under off conditions, indi-
cating binding and inactivation of these proteins by Bcl-xL. 
Upon induction of Nbk expression in the absence of doxy-
cycline, Nbk was coprecipitated with Bcl-xL, whereas coprecipita-
tion of Bak and, even more pronounced, of Bax with Bcl-xL was 
reduced. This indicates that Nbk binds to Bcl-xL, thereby par-
tially displacing Bak from Bcl-xL and almost completely freeing 
Bax from its binding to Bcl-xL. Identical results were obtained 
after down-regulation of Mcl-1. However, as shown in Fig. 8, 
only after down-regulation of Mcl-1 did Nbk expression induce 
activation of Bak.
The functional studies established that Nbk-induced cell 
death is increased after down-regulation of Mcl-1 (Fig. 7). 
  Regarding a displacement model for activation of Bax/Bak by 
BH3-only proteins, the knockdown of Mcl-1 may cause the re-
lease of BH3-only proteins bound to Mcl-1, such as Puma and 
Bim, which could render the system more sensitive to apoptosis. 
Figure 6.  Nbk expression stabilizes Mcl-1 levels independently of Puma. 
DU145 were treated with control siRNA or, to down-regulate Puma, with 
siRNA against Puma mRNA. 24 h later, cells were transduced with either 
Ad-mycNbk-tTA or Ad-mycPuma-tTA and cultured for an additional 24 h 
under off or on conditions. As control, cells were cultured with or without 
20 μM ubiquitin proteasome inhibitor MG132 (MG). Protein levels were 
analyzed by immunoblotting. Mcl-1 levels were increased in the presence 
of Nbk or Puma expression. Stabilization of Mcl-1 by Nbk is independent 
of Puma, as Nbk stabilizes Mcl-1 even after down regulation of Puma by 
siRNA. For Bcl-2, a positive control was added (far right).CONTROL OF BAK BY MCL-1 IN NBK RESISTANCE • GILLISSEN ET AL. 709
To study a putative role of these BH3-only proteins in Nbk-
induced apoptosis, we analyzed the effect of siRNA-mediated 
down-regulation of Bim, Puma, or both in Bax-defi  cient DU145 
mock cells after knockdown of Mcl-1. Knockdown of the prespec-
tive proteins was confi  rmed by Western blot analysis (Fig. 9 A). 
Down-regulation of Mcl-1 sensitized these Bax-defi  cient/Bak-
expressing DU145 cells for Nbk-induced apoptosis. Neverthe-
less, the additional knockdown of Bim, Puma, or both failed to 
affect Nbk-induced apoptosis. Upon induction of Nbk,  26% 
of cells showed sub-G1 DNA content regardless of Puma or 
Bim expression (Fig. 9 B). Finally, the Mcl-1 inhibitor Noxa is 
barely detectable in DU145 cells (unpublished data). These re-
sults demonstrate that sensitization to Nbk-induced apoptosis 
after down-regulation of Mcl-1 is a direct effect of Nbk that is 
independent from these additional BH3-only proteins.
Discussion
Nbk is a BH3-only protein that is expressed in a restricted subset 
of human epithelial tissues with strongest expression in the kidney 
(Daniel et al., 1999). In line with a potential role of Nbk in tumor 
suppression, loss of Nbk is a common feature of renal cell  carcinoma 
(Sturm et al., 2006), and the chromatin locus 22p13.3, which con-
tains nbk, is frequently deleted in human colorectal and breast 
cancers (Castells et al., 1999). Expression of Nbk triggers apopto-
sis in breast, lung, prostate, and colon carcinoma, as well as glioma- 
and melanoma-derived cell lines (Tong et al., 2001; Germain 
et al., 2002; Gillissen et al., 2003; Oppermann et al., 2005).
Because Nbk is a constitutively active protein, it is mainly 
regulated on the transcriptional level, and induction of Nbk in 
response to genotoxic stress is mediated in a p53-dependent 
manner (Mathai et al., 2002, 2005). Based on previous analyses 
that Bax defi  ciency protects cancer cells from Nbk-induced 
apoptosis, even though these cells retain expression of the Bax 
homologous protein Bak, it appears that the proapoptotic func-
tion of Nbk depends on the presence of Bax but not of Bak 
(Theodorakis et al., 2002; Gillissen et al., 2003).
Interestingly, it has been suggested most recently that 
BH3-only proteins can function via two mutual, yet not exclu-
sive, modes of action (Letai et al., 2002; Kuwana et al., 2005). 
For the BH3-only proteins tBid, Bim, and, more controversially, 
Puma (Cartron et al., 2004), a physical interaction and direct 
activation of both Bax and Bak has been proposed. These BH3-
only proteins were therefore described as direct activators.
Figure 7.  siRNA silencing of Mcl-1 sensitizes Bak-proﬁ  cient 
DU145 cells for Nbk-induced apoptosis and cytochrome c 
release. Mcl-1 was down-regulated in DU145 mock and Bak 
cells by use of siRNA. 24 h later, cells were transduced with 
Ad-mycNbk-tTA to induce Nbk expression and cultured for 
additional 24 h under off or on conditions. (A) SiRNA silencing 
of Mcl-1, overexpression of Nbk, and the Bax expression status 
were conﬁ  rmed by Western blot analysis. (B) The percentage 
of apoptotic cells was determined by ﬂ  ow cytometric measure-
ment of hypodiploid DNA. Data are means ± SD from three 
independent experiments. (C) Cytosolic extracts were prepared 
and subjected to immunoblotting to analyze Nbk-induced cyto-
chrome c release after down-regulation of Mcl-1.JCB • VOLUME 179 • NUMBER 4 • 2007  710
Figure 8.  Knockdown of Mcl-1 facilitates conformational switch and clustering of Bak upon Nbk expression. 24 h after Mcl-1 down-regulation, cells were 
transduced with Ad-mycNbk-tTA and cultured for an additional 24 h under off or on conditions. (A) Cells were stained with a conformation-speciﬁ  c antibody 
against the Bak N terminus and analyzed by ﬂ  ow cytometry. The percentage of immunostained cells is indicated between markers. A representative experi-
ment is shown (top). Data are means ± SD from three independent experiments (bottom). (B) Clustering of EGFP-Bak under on conditions after siRNA repres-
sion of Mcl-1. Bar, 50 μm. (C) Bak shows a more reticular localization that is in agreement with its constitutive association with mitochondria (left). 
In apoptotic cells, Bak coalesces into large clusters adjacent to mitochondria (right). Bar, 25 μm. (D) Coimmunoprecipitation analyses of Bcl-xL. Cell lysates 
were prepared as described in Materials and methods. Bcl-xL–Bax and Bcl-xL–Bak interaction were strongly diminished after Nbk expression in the presence 
of Mcl-1 (top) and after down-regulation of Mcl-1 by use of siRNA (bottom).CONTROL OF BAK BY MCL-1 IN NBK RESISTANCE • GILLISSEN ET AL. 711
The other mode of BH3-only proteins is derepression, which 
means the release of proapoptotic potential of Bax or Bak by 
counteracting the inhibitory effect of antiapoptotic Bcl-2 proteins. 
Derepressors can release Bax and/or Bak from their inhibitory 
antiapoptotic counterparts through competitive binding of their 
BH3 domain to antiapoptotic Bcl-2 proteins. Strong evidence 
for the derepressor model comes from the observation that Bax 
and Bak can mediate apoptosis without discernable association 
with the putative BH3-only activators (Bim, Bid, and Puma), 
even in cells with no Bim or Bid and reduced Puma (Willis 
et al., 2007).
Nbk interacts with antiapoptotic Bcl-2 family members, 
but not with the proapoptotic multidomain proteins Bax (Boyd 
et al., 1995; Han et al., 1996; Elangovan and Chinnadurai, 1997; 
Gillissen et al., 2003) and Bak, indicating that Nbk functions 
as a derepressor to activate apoptosis. However, regarding the 
proposed rheostat model where the relative concentration of 
antiapoptotic, Bcl-2–like, and proapoptotic family members 
determines the fate of a cell, the role of Bak in Nbk-induced 
apoptosis is poorly investigated.
In this study we demonstrate that specifi  c loss of Bax, 
but not of Bak, confers resistance to Nbk-induced apoptosis. 
Furthermore, we show that, in contrast to Bax reexpression, 
expression of Bak does not sensitize Bax-defi  cient DU145 
cells for Nbk-induced cell death. Nbk fails to induce clustering 
and oligomerization of EGFP-Bak fusion protein but induces 
strong EGFP-Bax translocation. This demonstrates that Nbk-
mediated apoptosis ultimately depends on Bax, whereas Bak 
is dispensable.
Interestingly, Bak is sequestered by the antiapoptotic pro-
teins Bcl-xL and Mcl-1 (but not by Bcl-2), and activation of Bak 
requires neutralization of both proteins Bcl-xL and Mcl-1 by 
BH3-only family members (Willis et al., 2005). In turn, we 
showed that Nbk interacts with Bcl-xL, but interaction with 
Mcl-1 could not be detected. Moreover, Nbk fails to disrupt 
Mcl-1–Bak interaction. Notably, Bak is sequestered and inacti-
vated by Mcl-1, even in the presence of strong Nbk expression. 
This is in contrast to Puma, which binds to Bcl-xL and Mcl-1 
and releases Bak from Mcl-1 binding. In this context, it is inter-
esting that peptides derived from BH3-only domains exhibit 
differences in their binding selectivity to antiapoptotic Bcl-2 
proteins. Determination of the binding constants by Biacore ex-
periments revealed that Puma potently engaged all the pro-
survival proteins, including Mcl-1, whereas Nbk showed very low 
affi  nity to Mcl-1 (Chen et al., 2005). Thus, it appears to be reason-
able that Nbk blocks the inhibitory function of Bcl-xL on Bak, 
Figure 9.  Mcl-1 siRNA–induced sensitization to Nbk is 
independent of Bim and Puma. 24 h before transduc-
tion of Bax-deﬁ   cient DU145 cells with Ad-mycNbk-tTA, 
Mcl-1 was down-regulated by use of siRNA to facilitate 
Bak activation. To assess a putative role of other BH3-
only proteins, Puma and Bim expression were blocked 
by siRNA. DU145 cells were then cultured for 24 h un-
der off or on conditions to repress or induce Nbk ex-
pression, respectively. Control cells were mock treated. 
(A) Expression levels of the indicated proteins were 
  analyzed by immunoblotting. (B) Apoptosis was deter-
mined by ﬂ  ow cytometric measurement of genomic DNA 
fragmentation. Cells displaying sub-G1 hypodiploid DNA 
content are considered apoptotic. Data are means ± SD 
from three independent experiments.JCB • VOLUME 179 • NUMBER 4 • 2007  712
but the antiapoptotic Mcl-1 is capable of backing up and still 
keeping Bak in check as a second restraint. Inhibition of Bak by 
Mcl-1, which in turn cannot be inactivated by Nbk, is therefore 
responsible for the failure of Nbk to induce Bak activation. 
Indeed, down-regulation of Mcl-1 by siRNA sensitizes Bax-
defi  cient DU145 cells for Nbk-induced apoptosis and enables 
Nbk to activate Bak. This hints at a staggered barrier formed by 
antiapoptotic proteins, which is counteracted by the likewise 
graduated proapoptotic potential of BH3-only proteins.
Mcl-1 is readily down-regulated in response to certain death 
stimuli. The short half-life of Mcl-1 is attributed to constitutive 
polyubiquitination and subsequent degradation of Mcl-1 by the 
proteasome, which is a prerequisite for induction of apoptosis 
after UV irradiation (Nijhawan et al., 2003). Polyubiquitination of 
Mcl-1 is catalyzed, e.g., by Mule/ARF-BP1, a novel E3 ubiquitin 
ligase that binds to Mcl-1 via a BH3 domain and marks Mcl-1 
for proteasomal degradation (Zhong et al., 2005). The BH3-only 
protein Noxa also plays a crucial role in Mcl-1 degradation. 
By displacing Bak from Mcl-1, Noxa enhances polyubiquitination 
and subsequent proteasomal degradation of Mcl-1 (Willis et al., 
2005). In contrast to Noxa-induced degradation of Mcl-1, we 
found that the cellular Mcl-1 protein level was even increased 
after Nbk expression. This effect of Nbk expression was specifi  c 
for Mcl-1 and was not observed for Bcl-2 or Bcl-xL. A similar 
phenomenon has been previously reported in the context of 
Puma overexpression. In these experiments, Mcl-1 was stabilized 
by binding to Puma, and it has been suggested that the inter-
action between Mcl-1 and Puma and the resulting stabilization 
of Mcl-1 may represent a novel mechanism to regulate and pre-
vent apoptosis (Mei et al., 2005). However, Mcl-1 is stabilized by 
Nbk even when Puma is knocked down. Thus it is unlikely that 
Puma, after being displaced from Bcl-xL by Nbk, mediates Mcl-1 
stabilization in this setting. In our experimental system, persis-
tent binding of Bak to Mcl-1 might therefore be responsible 
for enhanced Mcl-1 expression via stabilization, as Nbk, unlike 
Puma, does not bind to Mcl-1 to displace Bak. Consistent with 
these data, we found that adenoviral overexpression of Puma, 
despite stabilizing Mcl-1, can induce apoptosis in a Bak-  dependent 
manner (in Bax-defi  cient DU145 Bak cells), although to a lesser 
extent compared with DU145 Bax cells (unpublished data). 
Therefore, stabilization of Mcl-1 may exert distinct regulatory 
functions in the fi  ne-tuning of apoptosis and attenuating Puma-
induced apoptosis. Moreover, Mcl-1 stabilization by Nbk inter-
feres with activation of Bak because Nbk, in contrast to Puma, 
fails to bind and inactivate Mcl-1. Thus, in Nbk-induced apopto-
sis, Bak cannot compensate for Bax because of the low affi  nity 
of Nbk to Mcl-1 and the up-regulation of Mcl-1 after expression 
of Nbk, which may further interfere with activation of Bak. 
Support for this model comes from the observation that the BH3-
only protein Noxa, which targets Mcl-1, cooperates with Nbk 
to activate mitochondrial cytochrome c release; however, the 
impact on Bak activation was not addressed in this study and 
all experiments were performed in a Bax-profi  cient background 
(Germain et al., 2005).
Collectively, our data support a model in which the pro-
apoptotic activity of BH3-only proteins is governed by their 
propensity to interfere with an at least dual layer of protection 
of Bak (Willis and Adams, 2005). In our system, binding of Nbk 
inactivates Bcl-xL and releases Bax and Bak (Fig. 10). Although 
the interaction between Nbk and Bcl-xL seems to be stronger, 
Nbk also binds to Bcl-2 (Elangovan and Chinnadurai, 1997; 
Verma et al., 2001; Gillissen et al., 2003), indicating that Bcl-2 
is at least partially inhibited by Nbk. Once the capacity of Bcl-2 
to bind Bax is exceeded, the unbound Bax protein becomes 
  activated. Notably, the Bax inhibitors Bcl-2 and Bcl-xL are not 
stabilized by Nbk. In contrast, Bak, released from Bcl-xL upon 
Nbk expression, is still kept in check by Mcl-1, and this is even 
enforced by the up-regulation of the Bak inhibitor Mcl-1 by 
Nbk. This Bak inhibition may be further supported by other fac-
tors that do not necessarily belong to the Bcl-2 family, such as 
the VDAC2 protein (Cheng et al., 2003; Chandra et al., 2005). 
Mcl-1–mediated repression of Bak thereby provides a molecu-
lar rationale for the strict Bax dependency of apoptosis induced 
by Nbk in the present setting. Thus, BH3-only proteins that, like 
Nbk, act as derepressors bind to distinct antiapoptotic proteins. 
Nevertheless, the consequently derepressed proapoptotic multi-
domain proteins can then be counteracted by a second row of 
antiapoptotic proteins. This adds a higher degree of specifi  city 
and opportunities for the fi  ne-tuning of death signals. The out-
come of triggering this tightly balanced interaction network 
would be dictated by both the mix of BH3-only proteins in-
duced by a given death stimulus and the abundance of their anti-
apoptotic counterparts forming this second barrier to apoptosis. 
Support for the biological relevance of such a Bak inhibitor 
Figure 10.  Model for the regulation of Nbk-induced apoptosis by Bcl-2 
family members. (A) In healthy cells, Bax is inactivated by Bcl-2 and Bcl-xL, 
whereas Bak is sequestered by Bcl-xL and Mcl-1. (B) Nbk activates the 
proapoptotic Bax through neutralization of the antiapoptotic Bcl-xL. In con-
trast, increased levels of the antiapoptotic Mcl-1 keep in check Bak that was 
released from Bcl-xL upon competition with Nbk.CONTROL OF BAK BY MCL-1 IN NBK RESISTANCE • GILLISSEN ET AL. 713
model comes indirectly from cancer biology. There, disruption 
of the bax gene impairs myc-induced islet cell depeletion upon 
myc expression and facilitates tumorigenesis in a myc-driven 
pancreatic β-cell tumor model, whereas genetic inactivation of 
bak has no impact (Dansen et al., 2006). In fact, loss of Bax is a 
frequent event in human cancer, whereas Bak expression per-
sists in most cancers. Thus, targeting Bak inhibitors should be a 
rewarding strategy to overcome restraints in apoptosis signaling 
in cancer and resulting resistance mechanisms.
Materials and methods
Cell culture and cell lines
HEK293 and DU145 cells were obtained from the American Type Culture 
Collection or the Deutsche Sammlung von Mikroorganismen und Zellkulturen. 
HCT116 wt cells and their isogeneic knockout sublines HCT116 Bax
−/Bak
− 
were provided by B. Vogelstein (Johns Hopkins Cancer Center, Baltimore, 
MD). The stable knockdown of Bak was performed in either HCT116 wt 
or HCT116 Bax knockout cells yielding Bax
+/Bak
– and Bax
–/Bak
– cells. 
Transfectants were generated and cells were cultured as previously described 
(Gillissen et al., 2003; von Haefen et al., 2004; Hemmati et al., 2006). 
Expression of BH3-only proteins was suppressed by addition of 1 μg/ml 
doxycycline to the culture medium (Tet-off condition).
Antibodies and immunoblotting
Monoclonal mouse anti-Bax antibody (clone YTH-2D2; raised against a 
peptide corresponding to aa 3–16) was purchased from Trevigen, Inc., 
and goat anti-Nbk antibody (N-19; raised against an epitope mapping to 
the 19-aa N terminus of human Nbk) and rabbit anti–Mcl-1 (H-260; epi-
tope corresponding to aa 1–260 mapping at the N terminus of Mcl-1 of hu-
man origin) were purchased from Santa Cruz Biotechnology, Inc. Polyclonal 
rabbit anti–Bcl-xS/L antibody (raised against aa 18–233 of rat Bcl-xL) and 
anti-Bim (against aa 22–40 of human Bim) were purchased from BD Bio-
sciences, monoclonal mouse anti–human cytochrome c (clone 7H8.2C12) 
was purchased from BD Biosciences, and goat anti–caspase-9 antibody 
(raised against human caspase-9 aa 139–330) was purchased from R&D 
Systems. The polyclonal rabbit anti-Bak antibody (raised against a peptide 
corresponding to aa 14–36) was purchased from Dako. Polyclonal anti–
human actin antibody and anti-Puma, produced in rabbits, were obtained 
from Sigma-Aldrich. Polyclonal anti–human caspase-3, produced in goat, 
was obtained from R&D Systems. Secondary anti–rabbit, anti–goat, and 
anti–mouse HRP-conjugated antibodies were obtained from Promega or 
SouthernBiotech. After cell trypsination and washing, protein expression 
was detected by ECL-based Western blot analysis as described previously 
(Gillissen et al., 2003). For analysis of cytochrome c release, cells were 
lysed in a hypotonic digitonin buffer as described previously (von Haefen 
et al., 2003).
Construction of recombinant adenovirus
The recombinant adenovirus for Puma or Bcl-xS expression was constructed 
for mycNbk as described previously (Gillissen et al., 2003). In brief, the E3 
region of Ad5 was replaced by tTA under the control of a CMV promoter 
and an SV40 poly(A) tail. A Puma or Bcl-xS cDNA was introduced into the 
E1 region under the control of the Tet-off system to achieve conditional ex-
pression in the absence of doxycycline. The resulting DNA construct was 
transfected in HEK293 packaging cells to produce vector stocks. Adeno-
viral stocks were propagated according to standard procedures described 
in Hemmati et al. (2002).
Measurement of apoptotic cell death by ﬂ  ow cytometry
Apoptosis was determined on a single-cell level by measuring the DNA 
content of individual cells with a FACScan (BD Biosciences) as described 
previously (Gillissen et al., 2003). Cellular DNA content was measured by 
ﬂ  ow cytometry with logarithmic ampliﬁ  cation in the FL-3 channel. Data are 
given in percentage of hypoploidy (sub-G1), which reﬂ  ects the percentage 
of apoptotic cells. Alternatively, apoptotic cell death was determined by 
PI staining and measuring binding of Annexin V–FITC upon exposure of 
phosphatidylserine to the cell surface (Gillissen et al., 2003).
Measurement of mitochondrial permeability transition
After infection with recombinant adenovirus at the MOI of 25 in the pres-
ence or absence of doxycycline, cells were collected by centrifugation at 
300 g at 4°C for 5 min. Mitochondrial permeability transition was deter-
mined by staining the cells with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-
benzimidazolylcarbocyanin iodide (JC-1; Invitrogen) as described previously 
(Gillissen et al., 2003). Mitochondrial permeability transition was then quanti-
ﬁ  ed by ﬂ  ow-cytometric determination of cells with decreased red ﬂ  uorescence, 
i.e., with mitochondria displaying a lower ∆Ψm.
Fluorescence microscopy
DU145 EGFP-Bax or EGFP-Bak cells were seeded on coverslips, infected 
with Ad-mycNbk-tTA, and cultured for 24 h under on or off conditions. 
Cells were washed with PBS and ﬁ  xed for 30 min with ice-cold 1% para-
formaldehyde. For immunoﬂ   uorescence staining of mitochondria, cells 
were permeabilized with ice-cold 100% methanol for 1 min. Cells were 
washed again, and nonspeciﬁ  c binding of antibodies was blocked by in-
cubation with 8% BSA for 30 min at room temperature. Primary antibodies 
(mouse anti–Tom 20 antibody [BD Biosciences]) were diluted in 1% BSA in 
PBS and added to the cells overnight at 4°C. Incubation with secondary 
antibodies (Alexa Fluor 594–conjugated chicken anti–mouse IgG [Invitro-
gen]) was performed for 1 h at room temperature. For staining of DNA, 
cells were incubated in PBS + DAPI for 5 min. Cells were washed and 
mounted in ﬂ  uorescence mounting medium (Dako). For overview images, 
cells were inspected at room temperature with a ﬂ  uorescent microscope 
(BX50; Olympus) equipped with a 40×/0.75 objective lens (UPlanFL; 
Olympus) and a camera (micropublisher 5.0 RTV; QImaging). For sub-
cellular localization pattern analysis, cells were inspected at room temper-
ature with a microscope (Axiovert 200; Carl Zeiss, Inc.) equipped with a 
63×/1.4 objective lens (Plan-Apochromat; Carl Zeiss, Inc.) and a digital 
camera (ORCA ER; Hamamatsu Photonics). Images were acquired by 
Openlab software (Improvision) and vertical slices (0.2-μm separation) 
were deconvoluted with Openlab 5.0.2 nearest–neighbor deconvolution 
algorithm on Mac OSX 10.4 (Apple Inc.).
Coimmunoprecipitation
Coimmunoprecipitations were performed using the ExactaCruz IP/Western 
blot reagents (Santa Cruz Biotechnology, Inc.) according to the manufac-
turer’s instructions. In brief, 1.5 × 10
6 cells/75-cm
2 ﬂ  ask were infected 
with Ad-mycNbk-tTA or Ad-Puma-tTA and cultured for 24 h with or without 
doxycycline. Cells were harvested and lysed as described previously 
(Gillissen et al., 2003). Lysates were precleared with preclearing matrix 
(Santa Cruz Biotechnology, Inc.). 150 μl of the precleared cellular extract 
was shaken in the presence of the IP antibody–IP matrix complex at 4°C 
for 4 h. Immunoprecipitations were done and examined by Western blot 
analysis as described previously (Gillissen et al., 2003).
RNA interference
Mcl-1 siRNA and control siRNA were purchased from Santa Cruz Biotech-
nology, Inc. Lipofection of the cells was performed by use of transfection re-
agent (Santa Cruz Biotechnology, Inc.) according to the manufacturer’s 
instructions. On-target plus siRNA against Puma, Bim, Mcl-1, and control 
siRNA for experiments shown in Figs. 6 and 9 was purchased from Dharma-
con. Transfection of the cells was performed by use of transfection reagent 
(DharmaFECT; Dharmacon) according to the manufacturer’s instructions. 
  After 24 h, cells were transduced with Ad-mycNbk-tTA at an MOI of 25.
Online supplemental material
Fig. S1 shows Nbk-induced phosphatidyl serine exposure of HCT116 cell 
lines. Fig. S2 shows changes of the subcellular localization pattern of 
EGFP-Bax and mitochondria after Nbk expression. Fig. S3 shows coimmuno-
precipitation studies of Puma and Bcl-xL. Fig. S4 shows Nbk-induced 
phosphatidyl serine exposure of DU145 cell lines after Mcl-1 knockdown. 
Fig. S5 shows subcellular localization pattern of EGFP-Bak and mito-
chondria upon Nbk expression. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.200703040/DC1.
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